Moderna, renowned for its highly effective mRNA COVID-19 vaccine, has announced the start of Phase 1 human trials for an mRNA-based HIV vaccine using the same proven technology.
In November 2020, Moderna unveiled its mRNA vaccine with 94.5% efficacy against SARS-CoV-2. It has since become a cornerstone of vaccination campaigns in numerous countries, alongside Pfizer and AstraZeneca vaccines. The company continues to advance mRNA technology, including a clinical trial for an influenza vaccine launched in July 2021.
Moderna's Phase 1 trial for an HIV vaccine, which causes AIDS, was detailed in an August 11, 2021, listing on the U.S. government's ClinicalTrials.gov platform. This initial two-year study will enroll 56 HIV-negative volunteers aged 18 to 50.
While both vaccines use mRNA, SARS-CoV-2 is a coronavirus with extensive research, whereas HIV remains challenging, particularly in its mechanisms of cell infection and replication.
With a limited cohort, Phase 1 will primarily assess safety by identifying potential side effects and confirm the vaccine's immunogenicity. Positive outcomes could lead to Phase 2 with expanded participants, followed by Phase 3—the final hurdle before potential market authorization.
Pharmaceutical leaders like Moderna have refined mRNA platforms for years, fueling optimism for breakthroughs against intractable diseases like HIV/AIDS, which affects over 37 million people worldwide. While effective treatments exist to manage the virus and prevent transmission, a vaccine remains elusive. These trials represent a critical advancement, though success is not guaranteed and development timelines are lengthy.
